the significance of the March 29/2021 announcement

 
Some people have asked about the significance of the recent (March 29/2021)  “Bioasis Announces Publication of CNS Delivery of siRNA via xB³ (TM) Platform Technology” announcement https://www.bioasis.us/bioasis-announces-publication-of-cns-delivery-of-sirna-via-xb%c2%b3-platform-technology/

The importance of this publication is that it is peer reviewed which is very important for credibility with scientists and potential partner companies.
The paper shows important controls - that indicate the studies were validly conducted and that the results seen with the xB3-siRNA are specific in knock-down of NOX4. These controls were not part of the original work and were needed for the paper to pass review and be accepted for publication.
The paper also shows that xB3 enters different brain cell types - astrocytes etc. A question often asked by Pharma companies.
Together these points make the technology “more proven/validated”.

Bottom line, the publication of this research validates the ability of the company’s xB 3 ™ platform to efficiently deliver siRNA across the blood-brain barrier to the central nervous system in therapeutically relevant doses.

 
As well, some people are confused about the timing of this news release – why now?
Does this have anything to do with the study data readouts shareholders are anticipating?

The article was published on March 26/2021 in the prestigious Frontiers in Molecular Biosciences publication which ranks as the 5th most-cited publisher among the 20 largest publishers in 2020 About Frontiers | Academic Journals and Research Community (frontiersin.org) so when did you want the company to release this news?
3 days after publication? A month after publication? 3 months after publication? Obviously the answer is as soon as possible after it was released publicly from Frontiers and that is what Bioasis did. This news has nothing to do with the study data readouts that are to be completed by the end of Q1/2021 and subsequently press released in the following weeks. I personally do not want to see three study readouts in one press release nor three separate press releases all announced on the same day as that is simply too much news for all interested parties to digest at once and makes no sense to do it that way. Let’s release them individually and allow them to be distributed and understood by the market. I’m certain shareholders and (potential) partners will be impressed! From my understanding, the studies we are awaiting data readouts for are in the 007, 004 and Progranulin programs.